ACN vs NOW
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Accenture (ACN) exhibits mixed fundamental health, with a Piotroski F-Score of 4/9 indicating a borderline stable financial position, and no Altman Z-Score available to assess distress risk. The stock trades at a premium to its Graham Number ($116.86) and intrinsic value estimate ($84.7), suggesting valuation is driven by growth expectations rather than conservative safety. Despite strong profitability metrics—ROE of 25.02% and gross margin of 31.97%—earnings growth has turned negative (-1.60% YoY), and recent price performance reflects significant underperformance over 1Y (-39.2%) and 5Y (-20.8%). Analysts remain optimistic with a buy recommendation and a target price of $268.51, but insider activity is neutral, and technical trends are bearish.
NOW shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Key strengths include strong valuation and growth metrics. Price trades at a 417.3% premium to fair value estimate ($20.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
ACN vs NOW: Head-to-Head Comparison
This page compares Accenture plc (ACN) and ServiceNow, Inc. (NOW) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.